Gandhi notes that the new study is small and observational, meaning it cant offer any conclusive pregnancy advice
FDA issued more than 58 warning letters addressing false or misleading claims about compounded GLP-1 products including compounded semaglutide and tirzepatide through late 2025 and early 2026, and followed with 30 further warning letters to telehealth companies in a single coordinated action in June 2026. In September 2025, the FDA also introduced a Green List import alert targeting active pharmaceutical ingredient (API) sources for GLP-1 products, restricting entry for foreign API manufacturers that have not demonstrated GMP compliance. Together, these actions show how quickly enforcement attention can pivot to a single product category a pattern directly relevant to any organization with exposure to compounding, telehealth-linked supply, or GLP-1 API sourcing
Any company currently marketing compounded GLP-1 products should conduct an immediate review of all advertising and promotional materials (including website content, social media, and direct-to-consumer communications) to ensure that no claims imply FDA approval, equivalency with branded products, or clinical validation that does not exist
You may also find it useful to read more about hCG on TRT in the UK, including fertility, benefits, and broader treatment considerations
Continue Reading Are your B12 injections not working
